Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 9/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1327872 | 0.91 | C5AR1 (0.39) | C5AR1SLC22A12MAPTHPGDFFAR4 | |
| SCHEMBL1329407 | 0.90 | C5AR1 (0.38) | C5AR1MAPTHPGDTSHRHTT | |
| SCHEMBL1327146 | 0.89 | C5AR1 (0.42) | C5AR1HTTALDH1A1 | |
| SCHEMBL1327763 | 0.89 | FFAR4 (0.41) | C5AR1MAPTTSHRFFAR4ALDH1A1 | |
| SCHEMBL1329169 | 0.87 | MEN1 (0.39) | C5AR1SLC22A12MAPTHTTFFAR4 | |
| SCHEMBL1329900 | 0.86 | C5AR1 (0.41) | C5AR1 | |
| SCHEMBL1327730 | 0.86 | C5AR1 (0.42) | C5AR1HTTFFAR4ALDH1A1 | |
| SCHEMBL1330106 | 0.86 | C5AR1 (0.42) | C5AR1MAPTHPGDTSHRHTT | |
| SCHEMBL1328110 | 0.86 | C5AR1 (0.36) | C5AR1SLC22A12FFAR4S1PR1 | |
| SCHEMBL1327921 | 0.86 | C5AR1 (0.37) | C5AR1SLC22A12MAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885SLC22A12 4405/4885MAPT 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.